knowledge -WSS

knowledge

author：leisure time 2025-09-27 16:49:36 - browse：35713

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

Advisers to the Food and Drug Administration voted 11-0 on Monday to recommend the approval of a drug for early Alzheimer’s disease made by Eli Lilly — ruling that the treatment’s ability to slow the cognitive decline in patients outweighed its safety risks.

The unanimous outcome of the daylong advisory panel was the best-case scenario for Lilly, making it likely that the FDA will approve the drug, called donanemab, for a broad population of people diagnosed with mild cognitive impairment due to Alzheimer’s. A decision is expected later this year.

“The benefits outweigh the risks, as long as the risks are being monitored,” said Kathleen Poston, a neurologist at Stanford University and a member of the advisory panel.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The cancer drug shortage isn’t new — and neither are the solutions
Next article： STAT Boddities: What happens to the brain when we get scared?

WSS

EU fines Illumina $475 million over Grail acquisition

Kerry to visit Beijing for climate talks amid efforts to revive relations between US and China

Is there an 'orca uprising'? Like orcas themselves, the answer is complex.

A Greenpeace activist is fined for crash

Digital health funding stays low as a new reality sets in

Grail's uphill battle for Medicare to cover its cancer screening test

focus

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

Continuity nursing helped my family in our darkest PICU moments

Here’s what’s in the FDA plan to include pregnant women in clinical trials

Continuity nursing helped my family in our darkest PICU moments

Study gives hint on South Asians’ higher risk of cardiovascular disease

Peter Hotez and the public health issue of online harassment

Vermont grapples with historic flooding as more rainstorms head for Northeast

Novavax promises a turnaround & Lilly roils the obesity market

Abbott's new heart device gets FDA advisory panel nod

Hollywood unions extend contract negotiations for actors

Abbott's new heart device gets FDA advisory panel nod

entertainment

Is there an 'orca uprising'? Like orcas themselves, the answer is complex.

Readout Newsletter: Replicate, Biogen's Leqembi, and Humira

Va. Republicans encourage early voting, a target of Trump's, ahead of fall elections

Tommy Tuberville reverses his claim that white nationalists are unfairly labeled racist

China sends large group of warplanes, navy ships towards Taiwan in forceful display

Artificial intelligence use in health care faces greater scrutiny in 2024

focus

focus

Wikipedia

explore